Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × enzalutamide × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 22 Prostatic Neoplasms, Castration-Resistant 4 Recurrence 2 Neoplasm Metastasis 2 Metastatic Castration-Resistant Prostate Cancer 2 mCRPC 1 Small Cell Lung Carcinoma 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Primary Dysautonomias 1 Pathologic Complete Response 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Hormone-sensitive Prostate Cancer 1 Lymphoma, Follicular 1 Kidney Diseases 1 Hypertension 1 Dementia 1 Cognitive Dysfunction 1 Breast Neoplasms 1 Bites and Stings 1 Biochemically Recurrent Prostate Cancer 1

Interventions

fludrocortisone acetate 1 enzalutamide 1 Prednisone 1 Hydrocortisone 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡